undamentalytics Newsletter
Sign in

Janux Therapeutics, Inc. income statement

In fiscal 2025, Janux Therapeutics, Inc. reported revenue of $10.0m, down 5.6% on the year before, operating income of −$158m (a -1576.7% margin) and net income of −$114m, or −$1.83 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0498111024
Research and development326535568126124
General and administrative2102226414244
Operating income−5−33−67−73−99−158−144
Income tax———000—
Net income−7−33−63−58−69−114−103
Diluted EPS−$7.41−$1.39−$1.52−$1.32−$1.28−$1.83−$1.64
Diluted shares (average)—24m41m44m54m62m62m
EBITDA−5−33−66−71−97−156−142

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CRSP vs JANXABEO vs JANXJANX vs STOK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Janux Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Janux Therapeutics, Inc.